Who is sponsoring NCT06767982?

NCT06767982 is sponsored by Ankara University.

What drugs are being tested in NCT06767982?

Interventions in NCT06767982: Bacillus Calmette-Guerin (BCG).

What condition does NCT06767982 study?

NCT06767982 studies Non Muscle Invasive Bladder Cancer.

Is NCT06767982 still recruiting?

NCT06767982 is currently completed. Last updated 10 January 2025.

Last reviewed 2025-01-10 · How we verify

NCT06767982

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)

Completed Phase 4 Last updated 10 January 2025

What this trial tests

Phase 4 trial testing Bacillus Calmette-Guerin (BCG) in Non Muscle Invasive Bladder Cancer in 160 participants. Completed in 31 December 2022.

Timeline

1 January 2019

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Ankara University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	160
Start date	1 January 2019
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Bacillus Calmette-Guerin (BCG) — full drug profile →

Conditions studied

Non Muscle Invasive Bladder Cancer — all drugs for Non Muscle Invasive Bladder Cancer →

Sponsor

Ankara University

Who can join

Eligibility, any sex, with Non Muscle Invasive Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare the efficacy and safety of two Bacillus Calmette-Guérin (BCG) substrains (RIVM and Russian) in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) in adult patients. The main questions it aims to answer are: * Is there a significant difference in recurrence-free survival (RFS) between the BCG RIVM and BCG Russian substrains? * Is there a significant difference in progression-free survival (PFS) between the two substrains? * Are there notable differences in the incidence of treatment-related adverse events between the strains? Researchers will compare patients treated with BCG RIVM to patients treated with BCG Russian to determine whether one substrain offers superior clinical outcomes in terms of recurrence, progression, and adverse events. Participants will: Undergo transurethral resection of bladder tumor (TURBT) prior to initiating therapy. Be randomly assigned to receive either BCG RIVM or BCG Russian intravesical therapy. Receive an induction course of six weekly instillations of the assigned BCG substrain. Receive maintenance therapy at regular intervals (3, 6, 12, 18, 24, 30, and 36 months) based on risk classification. Undergo regular follow-up with cystoscopy and urine cytology to assess recurrence, progression, and adverse events.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Engineered bacteria for cancer therapy: Advancements, challenges, and future directions.
Wang M, Liu M, Wang D, Yang D, et al · · 2025 · PMID 41243447 · DOI 10.1097/cm9.0000000000003807

Verify or expand the search:

Other trials of Bacillus Calmette-Guerin (BCG)

Trials testing the same drug.

NCT04507126 — A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults. · Phase 2 · completed
NCT03528694 — Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasiv · Phase 3 · active not recruiting

Other recruiting trials for Non Muscle Invasive Bladder Cancer

Currently open trials in the same condition.

NCT07283835 — Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Gue · Phase 2 · recruiting
NCT07036731 — A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Pati · NA · recruiting
NCT06181266 — A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer · Phase 1 · active not recruiting
NCT05981131 — Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC) · active not recruiting
NCT06287541 — The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative · NA · recruiting

Other Ankara University trials

Trials by the same sponsor.

NCT07441837 — Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients · Phase 2 · not yet recruiting
NCT07536490 — Sleep Quality, Cognition, and Disease Severity in Parkinson's Disease · not yet recruiting
NCT06959433 — Lu-177 PSMA Treatment in Cell Renal Carcinoma · Phase 3 · not yet recruiting
NCT07513272 — EFFECT OF BALLS ON PAIN AND ANXIETY DURING VENIPUNCTURE IN CHILDREN · NA · not yet recruiting
NCT07536542 — Effects of Dual-Task Training on Upper Extremity Function in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06767982 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ankara University
Last refreshed: 10 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06767982.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing